Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. Chronic use of Saint John's wort (SJW) has been shown to lower the bioavailability for a variety of co-administered drugs including indinavir, cyclosporin, and digoxin. Decreases in intestinal absorption through induction of the multidrug resistance transporter,
P-glycoprotein
(
P-gp
), may explain decreased bioavailability. 2. The present study characterized the response of
P-gp
to chronic and acute exposure of SJW and hypericin (
HYP
, a presumed active moiety within SJW) in an in vitro system. Experiments were performed with 3 to 300 microg ml(-1) of methanol-extracted SJW and 0.03 to 3 microM
HYP
, representing low to high estimates of intestinal concentrations. 3. In induction experiments, LS-180 intestinal carcinoma cells were exposed for 3 days to SJW,
HYP
, vehicle or a positive control (ritonavir).
P-gp
was quantified using Western blot analysis.
P-gp
expression was strongly induced by SJW (400% increase at 300 microg ml(-1)) and by
HYP
(700% at 3 microM) in a dose-dependent fashion. Cells chronically treated with SJW had decreased accumulation of rhodamine 123, a
P-gp
substrate, that was reversed with acute verapamil, a
P-gp
inhibitor. Fluorescence microscopy of intact cells validated these findings. In Caco-2 cell monolayers, SJW and
HYP
caused moderate inhibition of
P-gp
-attributed transport at the maximum concentrations tested. 4. SJW and
HYP
significantly induced
P-gp
expression at low, clinically relevant concentrations. Similar effects occurring in vivo may explain the decreased bioavailability of
P-gp
substrate drugs when co-administered with SJW.
...
PMID:Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. 1173 35